RT @gurdeep_dulay: Upto 30% risk of #RA within 5 yrs if anti-CCP positive #RNL23 https://t.co/E5wun837ud
Tweet Content
Upto 30% risk of #RA within 5 yrs if anti-CCP positive
#RNL23 https://t.co/E5wun837ud
RT @ericdeinmd: Conaghan: "Most promising study in OA" at #RNL2023 NGF inhibitor to OA had benefit, but very poorly tole
Tweet Content
Conaghan: "Most promising study in OA" at #RNL2023
NGF inhibitor to OA had benefit, but very poorly tolerated - could this be a future tolerated?
Can there be sustained response.
Conaghan: "In meantime, keep everybody strong" as primary treatment! 💪
@RheumNow https://t.co/eBMEPBG9wn
RT @NoufAhmedAlham2: Stop RA trail: Plaquenil didnât prevent RA in patient with pre clinical RA. Kevin Deane #RNL2023
Tweet Content
Stop RA trail:
Plaquenil didn’t prevent RA in patient with pre clinical RA. Kevin Deane #RNL2023 @RheumNow https://t.co/2Y5am2YEsQ
RT @ericdeinmd: Conaghan shares unpublished data from PROMOTE study at #RNL2023 Early data shows MTX benefits pain in pa
Tweet Content
Conaghan shares unpublished data from PROMOTE study at #RNL2023
Early data shows MTX benefits pain in patients w/ OA, particularly more metabolically active.
Looking forward to more data on this - though many many many DMARD trials thus far have been disappointing in OA
@RheumNow https://t.co/Ieagp8mq31
RT @NoufAhmedAlham2: 30% rule! Risk of RA development in Pre clinical RA patient in the next 3 to 5 years . Kevin De
Tweet Content
30% rule!
Risk of RA development in Pre clinical RA patient in the next 3 to 5 years .
Kevin Deane #RNL2023 @RheumNow https://t.co/J6Polz70im
RT @ericdeinmd: Dr Philip Conaghan at #RNL2023 X-rays are misleading in OA OA is a CLINICAL disease Radiographs do not h
Tweet Content
Dr Philip Conaghan at #RNL2023
X-rays are misleading in OA
OA is a CLINICAL disease
Radiographs do not help in diagnosis or monitoring
@RheumNow https://t.co/ZrAfPN02qi
RT @ericdeinmd: #RNL2023 @RheumNow There are a lot of RA Rx on market now - do we need more? Dr. Brenner: YES Stromal t
Tweet Content
#RNL2023 @RheumNow
There are a lot of RA Rx on market now - do we need more?
Dr. Brenner: YES
Stromal targets like LIF/LIFR, Notch3, cadherin-11 offer upstream benefits for our difficult to treat RA patients that don't respond to tradition cs/bDMARDs https://t.co/zJRRisGW9i
RT @ericdeinmd: @RheumNow Live #RNL2023 Stanley Cohen, MD: Use of JAK inhibitor in patients with known ASCVD: Number nee
Tweet Content
@RheumNow Live #RNL2023
Stanley Cohen, MD:
Use of JAK inhibitor in patients with known ASCVD: Number needed to harm 16
ASCVD is biggest risk factor for MACE events with JAKi https://t.co/gXNUOO8seG
RT @ericdeinmd: Dr Brenner at #RNL2023 Excellent description on how fibroblasts are major producers of IL-6 producers Cl
Tweet Content
Dr Brenner at #RNL2023
Excellent description on how fibroblasts are major producers of IL-6 producers
Clinically presents a target for blocking the fibroblasts, upstream the inflammatory cascade in RA
@RheumNow https://t.co/TserFZtvhV
RT @doctorRBC: JAKinib safety takeaways - avoid in older population > 65 yo, malignancy, CV risk, VTE risk - appropri
Tweet Content
JAKinib safety takeaways
- avoid in older population > 65 yo, malignancy, CV risk, VTE risk
- appropriate in younger pts without VTE/CVD risk factors
#RNL2023 @RheumNow https://t.co/5i1bRqqr7g
